Sidney Wolfe writes in the BMJ - AllTrials - Selective clinical trial
reporting: betraying trial participants, harming patients
Reporting biases found in trials of cardiovascular devicesReporting biases in published trials were first identified in 1986.1 Published randomized studies of combination chemotherapy compared with treatment with an alkylating agent as first line treatment for ovarian cancer showed a significant survival advantage for combination chemotherapy. Unpublished cancer trial registry data from the same studies, however, showed no such advantage.2 Similarly, in the treatment of multiple myeloma, registry data suggested a smaller survival advantage for combination chemotherapy (over prednisone and an alkylating agent) tha...
Source: PharmaGossip - June 11, 2015 Category: Pharmaceuticals Authors: insider Source Type: blogs
Sidney Wolfe writes in the BMJ - AllTrials - Selective clinical trial reporting: betraying trial participants, harming patients
Reporting biases found in trials of cardiovascular devicesReporting biases in published trials were first identified in 1986.1 Published randomized studies of combination chemotherapy compared with treatment with an alkylating agent as first line treatment for ovarian cancer showed a significant survival advantage for combination chemotherapy. Unpublished cancer trial registry data from the same studies, however, showed no such advantage.2 Similarly, in the treatment of multiple myeloma, registry data suggested a smaller survival advantage for combination chemotherapy (over prednisone and an alkylating agent) tha...
Source: PharmaGossip - June 11, 2015 Category: Pharmaceuticals Authors: insider Source Type: blogs
Sidney Wolfe writes in the BMJ - AllTrials - Selective clinical trial
reporting: betraying trial participants, harming patients
Reporting biases found in trials of cardiovascular devicesReporting biases in published trials were first identified in 1986.1 Published randomized studies of combination chemotherapy compared with treatment with an alkylating agent as first line treatment for ovarian cancer showed a significant survival advantage for combination chemotherapy. Unpublished cancer trial registry data from the same studies, however, showed no such advantage.2 Similarly, in the treatment of multiple myeloma, registry data suggested a smaller survival advantage for combination chemotherapy (over prednisone and an alkylating agent) tha...
Source: PharmaGossip - June 10, 2015 Category: Pharmaceuticals Authors: insider Source Type: blogs
Sidney Wolfe writes in the BMJ - AllTrials - Selective clinical trial
reporting: betraying trial participants, harming patients
< h1 class="title" style="font: -apple-system-headline; font-weight: normal; -webkit-hyphens: manual; max-width: 100%;" > < br > < /h1 > < span style="max-width: 100%; -webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);" > < /span > < div style="max-width: 100%;" > < p style="max-width: 100%;" > < span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);" > Reporting biases found in trials of cardiovascular devices < /span > < /p > < /div > < p style="max-width: 100%;" > < span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);" > Reporting bia...
Source: PharmaGossip - June 10, 2015 Category: Pharmaceuticals Authors: insider Source Type: blogs
Venous thromboembolism in cancer – Cardiology MCQ
Which of the following cancer has the highest relative risk of venous thromboembolism?
a) Pancreatic cancer
b) Brain cancer
c) Multiple myeloma
d) Colonic cancer
Correct answer: c) Multiple myeloma
Multiple myeloma has forty six fold risk of venous thromboembolism than healthy controls while brain cancer has twenty fold and pancreatic cancer sixteen fold relative risk. But by absolute numbers, most episodes occur with lung, colon and prostate cancer [1]. Chemotherapy confers six fold extra risk though chemotherapy per se is not considered an indication for prophylactic anticoagulation in ambulatory patients, the exceptio...
Source: Cardiophile MD - June 2, 2015 Category: Cardiology Authors: Prof. Dr. Johnson Francis, MD, DM, FACC, FRCP Edin, FRCP London Tags: Cardiology MCQ DM / DNB Cardiology Entrance Source Type: blogs
